The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance.

Autor: Murithi JM; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA., Pascal C; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Bath J; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA., Boulenc X; Sanofi Pasteur, Marcy L'Etoile, France., Gnädig NF; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA., Pasaje CFA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Rubiano K; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA., Yeo T; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA., Mok S; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA., Klieber S; Sanofi R&D, Translational Medicine & Early Development, Montpellier, France., Desert P; Sanofi Pasteur, Marcy L'Etoile, France., Jiménez-Díaz MB; The Art of Discovery, Bizkaia, Basque Country, Spain., Marfurt J; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia., Rouillier M; Medicines for Malaria Venture, Geneva, Switzerland., Cherkaoui-Rbati MH; Medicines for Malaria Venture, Geneva, Switzerland., Gobeau N; Medicines for Malaria Venture, Geneva, Switzerland., Wittlin S; Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.; Universität Basel, Basel, Switzerland., Uhlemann AC; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA., Price RN; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand., Wirjanata G; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia., Noviyanti R; Eijkman Institute for Molecular Biology, Jakarta, Indonesia., Tumwebaze P; Infectious Diseases Research Collaboration, Kampala, Uganda., Cooper RA; Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA, USA., Rosenthal PJ; Department of Medicine, University of California, San Francisco, CA, USA., Sanz LM; Global Health Pharma Research Unit, GSK, Tres Cantos, Madrid, Spain., Gamo FJ; Global Health Pharma Research Unit, GSK, Tres Cantos, Madrid, Spain., Joseph J; Syngene International Ltd., Bangalore, India., Singh S; Syngene International Ltd., Bangalore, India., Bashyam S; Syngene International Ltd., Bangalore, India., Augereau JM; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Giraud E; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Bozec T; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Vermat T; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Tuffal G; Sanofi R&D, Translational Medicine & Early Development, Montpellier, France., Guillon JM; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Menegotto J; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Sallé L; Sanofi R&D, Translational Medicine & Early Development, Montpellier, France., Louit G; Sanofi, Vitry-sur-Seine, France., Cabanis MJ; Sanofi R&D, Translational Medicine & Early Development, Montpellier, France., Nicolas MF; Sanofi, Vitry-sur-Seine, France., Doubovetzky M; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Merino R; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Bessila N; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Angulo-Barturen I; The Art of Discovery, Bizkaia, Basque Country, Spain., Baud D; Medicines for Malaria Venture, Geneva, Switzerland., Bebrevska L; Medicines for Malaria Venture, Geneva, Switzerland., Escudié F; Medicines for Malaria Venture, Geneva, Switzerland., Niles JC; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Blasco B; Medicines for Malaria Venture, Geneva, Switzerland., Campbell S; Medicines for Malaria Venture, Geneva, Switzerland., Courtemanche G; Bioaster, Paris, France., Fraisse L; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Pellet A; Sanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France., Fidock DA; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA. df2260@cumc.columbia.edu leroyd@mmv.org.; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA., Leroy D; Medicines for Malaria Venture, Geneva, Switzerland. df2260@cumc.columbia.edu leroyd@mmv.org.

Publikováno v: Science translational medicine [Sci Transl Med] 2021 Jul 21; Vol. 13 (603).

Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.

Autor: Doubovetzky M; Sanofi R&D, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France. Electronic address: m.doubovetzky@orange.fr., Ataman-Önal Y; Sanofi R&D, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France. Electronic address: yasemin.ataman-onal@sanofi.com., Chousterman B; Département d'Anesthésie-Réanimation-SMUR, Lariboisière Hospital, Paris, France. Electronic address: benjamin.chousterman@aphp.fr., Feroldi E; Sanofi R&D, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France. Electronic address: emmanuel.feroldi@sanofi.com., Garçon N; BIOASTER Microbiology Technology Institute, Lyon, France. Electronic address: nathalie.garcon@bioaster.org., Grillet MH; Safety Evaluation Group, Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France. Electronic address: Marie-Helene.Grillet@sanofi.com., Kramer D; Biomarkers & Clinical Bioanalyses Sanofi R&D, Frankfurt, Germany. Electronic address: Daniel.Kramer@sanofi.com., Laurent S; Sanofi R&D, Montpellier, France. Electronic address: sebastien.laurent2@sanofi.com., Lewis DJM; NIHR Imperial Clinical Research Facility, Imperial College Healthcare, NHS Trust, London, United Kingdom. Electronic address: d.lewis@nhs.net., Luna E; VaxDesign Campus, Sanofi Pasteur, Orlando, FL, United States. Electronic address: ernesto.luna@sanofi.com., Manigold T; University Hospital, Basel, Switzerland. Electronic address: tobias.manigold@usb.ch., Syntin P; Sanofi R&D, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France. Electronic address: patrick.syntin@sanofi.com., Burdin N; Sanofi R&D, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France. Electronic address: nicolas.burdin@sanofi.com., Fraisse L; Sanofi R&D, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France. Electronic address: lfraisse@dndi.org., Jackson N; Sanofi R&D, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France. Electronic address: nick.jackson@cepi.net.

Publikováno v: Vaccine [Vaccine] 2020 Dec 03; Vol. 38 (51), pp. 8055-8063. Date of Electronic Publication: 2020 Nov 10.

Rapid changes of mRNA expressions of cardiac ion channels affected by Torsadogenic drugs influence susceptibility of rat hearts to arrhythmias induced by Beta‐Adrenergic stimulation.

Autor: Hadova, Katarina¹ (AUTHOR), Kmecova, Jana^1,2 (AUTHOR), Ochodnicka‐Mackovicova, Katarina¹ (AUTHOR), Kralova, Eva¹ (AUTHOR), Doka, Gabriel¹ (AUTHOR), Bies Pivackova, Lenka¹ (AUTHOR), Vavrinec, Peter¹ (AUTHOR), Stankovicova, Tatiana¹ (AUTHOR), Krenek, Peter¹ (AUTHOR), Klimas, Jan¹ (AUTHOR) jan.klimas@uniba.sk

Publikováno v: Pharmacology Research & Perspectives. Oct2023, Vol. 11 Issue 5, p1-12. 12p.

Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.

Autor: Corbier A; Department of Disposition, Safety and Animal Research, Sanofi-aventis R&D, Vitry-sur-Seine 94400 France., Le Berre N, Rampe D, Meng H, Lorenz M, Vicat P, Potdevin S, Doubovetzky M

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2011 Jun; Vol. 121 (2), pp. 417-27. Date of Electronic Publication: 2011 Mar 24.

Molecular Docking Studies of Rifampicin – rpo B complex: Repurposing Drug Design Implications for against Plasmodium falciparum Malaria through a Computational Approach.

Autor: Yadav, Upasana, Pandey, Jaya

Publikováno v: Drug Research; Mar2023, Vol. 73 Issue 3, p164-169, 6p